Trial Profile
Phase II Study of Single Agent Obinutuzumab in Relapsed/Refractory Post-Transplant Lymphoproliferative Disorder (PTLD)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 24 Mar 2017
Price :
$35
*
At a glance
- Drugs Obinutuzumab (Primary)
- Indications Post-transplant lymphoproliferative disorder
- Focus Therapeutic Use
- 24 Mar 2017 New trial record